Lake Street Capital Begins Coverage on Ekso Bionics (NASDAQ:EKSO)

Lake Street Capital initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued to investors on Monday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $2.50 target price on the stock.

Other equities research analysts have also issued research reports about the stock. HC Wainwright lifted their price objective on shares of Ekso Bionics from $9.25 to $10.00 and gave the company a buy rating in a report on Tuesday, April 30th. StockNews.com assumed coverage on shares of Ekso Bionics in a report on Thursday, June 20th. They set a hold rating for the company.

Ekso Bionics Price Performance

Ekso Bionics stock opened at $1.02 on Monday. The firm has a 50-day moving average price of $1.21 and a 200-day moving average price of $1.60. The firm has a market capitalization of $18.54 million, a PE ratio of -1.05 and a beta of 1.49. The company has a current ratio of 2.81, a quick ratio of 2.11 and a debt-to-equity ratio of 0.33. Ekso Bionics has a 12-month low of $0.62 and a 12-month high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Monday, April 29th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.04). Ekso Bionics had a negative return on equity of 95.36% and a negative net margin of 79.48%. The firm had revenue of $3.76 million during the quarter, compared to the consensus estimate of $4.99 million. During the same quarter last year, the business posted ($0.33) EPS. As a group, equities research analysts forecast that Ekso Bionics will post -0.43 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Ekso Bionics stock. Strategic Wealth Investment Group LLC raised its holdings in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 21.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 51,950 shares of the company’s stock after purchasing an additional 9,285 shares during the period. Strategic Wealth Investment Group LLC owned 0.37% of Ekso Bionics worth $130,000 at the end of the most recent reporting period. 6.42% of the stock is owned by hedge funds and other institutional investors.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.